I-Mab, TRACON Pharmaceuticals begins human trial of CD73 antibody TJD5
Category: #health  By Pankaj Singh  Date: 2019-08-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

I-Mab, TRACON Pharmaceuticals begins human trial of CD73 antibody TJD5

The study will evaluate the tolerability and safety of TJD5 and determine recommended doses for future clinical studies.

I-Mab Biopharma (I-Mab), a clinical stage biopharmaceutical firm focused on the discovery and development of biologics in immuno-oncology, has announced that cancer drug maker TRACON Pharmaceuticals has dosed its first patient in a U.S. Phase 1 first-in-human clinical trial of CD73 antibody TJD5, a proprietary of I-Mab, in patients with advanced solid tumors.

According to reports, the company will dose TJD5 in the 1st Phase of its trials, both as a single agent and in combination with TECENTRIQ®, a PD-L1 antibody retailed by Roche. For the record, I-Mab and Roche entered into a research collaboration on April 2019, where Roche agreed to supply TECENTRIQ® to I-Mab for testing in combination with TJD5 in a clinical study.

Speaking on the announcement, Joan Shen, M.D., Ph.D., Head of R&D, I-Mab Biopharma, said that TJD5 is the third internally discovered drug developed by the company to enter clinical studies in the U.S. She said that the ‘Fast-to-PoC Global Approach’ plays an essential role for advancing the company’s proprietary drug candidates towards acceptance in the U.S, which further deepens their partnership with TRACON.

Shen added that the treatment resistance to PD-L1/ PD-1 inhibitors are one of the key challenges across cancer types and the company hopes the combination of TECENTRIQ® and TJD5 will offer a new treatment option to counter the unmet medical needs.

According to Charles Theuer, M.D., Ph.D., President and CEO, TRACON Pharmaceutical, signing this partnership contract with I-Mab is an essential milestone as both the parties have expanded their immune-oncology pipeline and validated TRACON’s product manufacturing capabilities designed to lower the time and cost of clinical development for its partners.

He said that their firm will continue to work with I-Mab to optimize the clinical development of TJD5, an antibody with best-in-class, global potential.

Source Credit: http://www.i-mabbiopharma.com/en/article-321.aspx

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Construction sector accountable for 37% of carbon emissions, UN report
Construction sector accountable for 37% of carbon emissions, UN report
By Pankaj Singh

A new research by the United Nations shows a grim picture of the climate situation. The report states that 37% of energy-related carbon dioxide emissions are coming from the construction sector. According to the UN, lockdowns imposed worldwide durin...

Alaska Airlines launches new investment arm to develop mobility tech
Alaska Airlines launches new investment arm to develop mobility tech
By Pankaj Singh

Alaska Airlines, a major American airline, has introduced a new venture capital subdivision called Alaska Star Ventures. The launch comes at a time when the aviation sector is looking to develop technologies that help decarbonize air travel. Alaska ...

Bettervest invests in Oakridge Rooftops to support solar projects
Bettervest invests in Oakridge Rooftops to support solar projects
By Pankaj Singh

Oakridge Rooftops Pvt. Ltd., a solar energy company based in India, has reportedly secured funding from Germany-based crowdfunding platform, Bettervest Gmbh. The solar firm has raised the funding for urban solar projects in New Delhi. Oakridge CEO, ...